Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD).
For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).
|11/20/19||8-K||Current report filing
|11/18/19||424B4||Prospectus filed pursuant to Rule 424(b)(4)||41|
|11/15/19||8-K||Current report filing||59|
|11/14/19||CORRESP||A correspondence can be sent as a document with another submission type or can be sent as a separate submission.||2|
|11/14/19||EFFECT||Notice of Effectiveness||1|
|11/14/19||S-1/A||General form of registration statement for all companies including face-amount certificate companies||51|
|11/14/19||8-K||Current report filing||3|
|11/14/19||S-1/A||General form of registration statement for all companies including face-amount certificate companies||190|
|11/08/19||FWP||Filing under Securities Act Rules 163/433 of free writing prospectuses||26|
|11/08/19||8-K||Current report filing||33|